Detalhe da pesquisa
1.
Treatment response lowers tumor symptom burden in recurrent and/or metastatic head and neck cancer.
BMC Cancer
; 20(1): 933, 2020 Sep 29.
Artigo
Inglês
| MEDLINE | ID: mdl-32993574
2.
Intracoronary autologous bone marrow cell transfer after myocardial infarction: the BOOST-2 randomised placebo-controlled clinical trial.
Eur Heart J
; 38(39): 2936-2943, 2017 Oct 14.
Artigo
Inglês
| MEDLINE | ID: mdl-28431003
3.
Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial.
Lancet Oncol
; 17(9): 1230-9, 2016 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-27501767
4.
Predictive role of hand-foot syndrome in patients receiving first-line capecitabine plus bevacizumab for HER2-negative metastatic breast cancer.
Br J Cancer
; 114(2): 163-70, 2016 Jan 19.
Artigo
Inglês
| MEDLINE | ID: mdl-26657657
5.
Serum Levels of Hepatitis B Surface Antigen Predict Severity of Fibrosis in Patients With E Antigen-Positive Chronic Hepatitis B.
Clin Gastroenterol Hepatol
; 13(8): 1532-9.e1, 2015 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-25542306
6.
Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial.
Lancet Oncol
; 14(2): 125-33, 2013 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-23312888
7.
Predicting early and sustained virological responses in prior nonresponders to pegylated interferon alpha-2b plus ribavirin retreated with peginterferon alpha-2a plus ribavirin and the benefit-risk ratio of retreatment.
J Clin Gastroenterol
; 47(9): 786-93, 2013 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-23442834
8.
Intensified peginterferon α-2a dosing increases sustained virologic response rates in heavy, high viral load hepatitis C genotype 1 patients with high low-density lipoprotein.
J Clin Gastroenterol
; 47(3): 271-9, 2013 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-22951527
9.
First-line cetuximab + platinum-based therapy for recurrent/metastatic head and neck squamous cell carcinoma: A real-world observational study-ENCORE.
Cancer Rep (Hoboken)
; 6(5): e1804, 2023 05.
Artigo
Inglês
| MEDLINE | ID: mdl-37069784
10.
Refined prediction of week 12 response and SVR based on week 4 response in HCV genotype 1 patients treated with peginterferon alfa-2a (40KD) and ribavirin.
J Hepatol
; 56(6): 1276-82, 2012 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-22314423
11.
Safety of peginterferon alfa-2a plus ribavirin in a large multinational cohort of chronic hepatitis C patients.
Liver Int
; 32(8): 1270-7, 2012 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-22621707
12.
Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection.
J Hepatol
; 55(1): 69-75, 2011 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-21145856
13.
Low-dose peginterferon alfa-2a is safe and produces a sustained virologic response in patients with chronic hepatitis C and end-stage renal disease.
Clin Gastroenterol Hepatol
; 9(3): 242-8, 2011 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-21056689
14.
Efficacy and safety of peginterferon alfa-2a (40KD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis.
Hepatology
; 51(2): 388-97, 2010 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-19918980
15.
Noninferiority of cetuximab every-2-weeks versus standard once-weekly administration schedule for the first-line treatment of RAS wild-type metastatic colorectal cancer.
Eur J Cancer
; 144: 291-301, 2021 02.
Artigo
Inglês
| MEDLINE | ID: mdl-33383349
16.
A Prospective Real-World Multi-Center Study to Evaluate Progression-Free and Overall Survival of Radiotherapy with Cetuximab and Platinum-Based Chemotherapy with Cetuximab in Locally Recurrent Head and Neck Cancer.
Cancers (Basel)
; 13(14)2021 Jul 08.
Artigo
Inglês
| MEDLINE | ID: mdl-34298628
17.
A multicenter prospective, randomized, placebo-controlled phase II/III trial for preemptive acute graft-versus-host disease therapy.
Leukemia
; 35(6): 1763-1772, 2021 06.
Artigo
Inglês
| MEDLINE | ID: mdl-33082512
18.
Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b: a randomized trial.
Ann Intern Med
; 150(8): 528-40, 2009 Apr 21.
Artigo
Inglês
| MEDLINE | ID: mdl-19380853
19.
Final analysis of the international observational S-Collate study of peginterferon alfa-2a in patients with chronic hepatitis B.
PLoS One
; 15(4): e0230893, 2020.
Artigo
Inglês
| MEDLINE | ID: mdl-32275726
20.
Annexin A3 in urine: a highly specific noninvasive marker for prostate cancer early detection.
J Urol
; 181(1): 343-53, 2009 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-19012935